Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNRHR known ✓ | P30968 | 20/20 | 0.88 |
| ▸ | CYP3A4 | P08684 | 11/20 | 0.88 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.88 |
| ▸ | APLNR | P35414 | 1/20 | 0.88 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.88 |
| ▸ | GLP1R | P43220 | 1/20 | 0.88 |
| ▸ | CX3CR1 | P49238 | 1/20 | 0.88 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.88 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.88 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1643219 | 1.00 | GNRHR (0.88) | GNRHRCYP3A4ADRB2APLNROPRK1 | |
| SCHEMBL5002181 | 0.94 | GNRHR (0.87) | GNRHRCYP3A4ADRB2APLNROPRK1 | |
| SCHEMBL1643488 | 0.94 | GNRHR (0.87) | GNRHRCYP3A4ADRB2APLNROPRK1 | |
| SCHEMBL1643218 | 0.93 | GNRHR (0.86) | GNRHRCYP3A4ADRB2APLNROPRK1 | |
| Elagolix SCHEMBL20741205 | 0.93 | GNRHR (1.00) | GNRHRCYP3A4ADRB2APLNROPRK1 | |
| SCHEMBL1643222 | 0.93 | GNRHR (0.86) | GNRHRCYP3A4ADRB2APLNROPRK1 | |
| Elagolix SCHEMBL1641994 | 0.93 | GNRHR (1.00) | GNRHRCYP3A4ADRB2APLNROPRK1 | |
| Elagolix SCHEMBL29394583 | 0.93 | GNRHR (1.00) | GNRHRCYP3A4ADRB2APLNROPRK1 | |
| SCHEMBL1644181 | 0.92 | GNRHR (0.80) | GNRHRCYP3A4ADRB2APLNROPRK1 | |
| Elagolix SCHEMBL4995673 | 0.92 | GNRHR (0.92) | GNRHRCYP3A4ADRB2APLNROPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11459305-B2 | Processes for the preparation of uracil derivatives | NEUROCRINE BIOSCIENCES, INC. (US) | 2022-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11459305-B2 | Processes for the preparation of uracil derivatives | GNRHR, FSHR, GHRHR | GNRHR 1/4885CYP3A4 1033/4885ADRB2 1892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.